Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zotiraciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 19/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 18/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 1/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 17/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 17/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zotiraciclib SCHEMBL30776189 | 1.00 | FLT3 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| Zotiraciclib SCHEMBL29358903 | 1.00 | FLT3 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| Zotiraciclib SCHEMBL29392459 | 1.00 | FLT3 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| Zotiraciclib SCHEMBL17595943 | 1.00 | FLT3 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL824014 | 0.91 | CDK2 (0.83) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL824049 | 0.90 | CDK2 (0.82) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL27369814 | 0.90 | JAK2 (0.82) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL823932 | 0.90 | CDK2 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| SCHEMBL824060 | 0.90 | FLT3 (1.00) | FLT3JAK2CDK2CCNA2CCNA1 | |
| Zotiraciclib SCHEMBL29422950 | 0.89 | FLT3 (0.80) | FLT3JAK2CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | claimed |
| EP-3432888-A1 | TREATMENT OF CANCER WITH TG02 | Tragara Pharmaceuticals, Inc. (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165732-A1 | TREATMENT OF CANCER WITH TG02 | TRAGARA PHARMACEUTICALS, INC. (US) | 2017-09-28 | — | — | WO | claimed |
| EP-3958854-B1 | TG02 FOR USE IN TREATING GLIOMAS IN PEDIATRIC SUBJECTS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2023005281-A1 | PREPARATION METHOD FOR AND APPLICATION OF NOVEL CDK9 INHIBITOR HAVING MACROCYCLIC SKELETON STRUCTURE | 中国药科大学 | 2023-02-02 | — | — | WO | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| WO-2011097525-A1 | SOLID STATE FORMS OF MACROCYCLIC KINASE INHIBITORS | TRAGARA PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | FLT3 424/4885JAK2 692/4885CDK2 13/4885 |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | FLT3 424/4885JAK2 692/4885CDK2 13/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | FLT3 2088/4885JAK2 3328/4885CDK2 3726/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | FLT3 4588/4885JAK2 4092/4885CDK2 1489/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | FLT3 3100/4885JAK2 3645/4885CDK2 894/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | FLT3 3646/4885JAK2 3482/4885CDK2 1540/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | FLT3 2026/4885JAK2 2882/4885CDK2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.